Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
2.840
+0.100 (3.65%)
At close: Nov 20, 2024, 4:00 PM
2.900
+0.060 (2.11%)
After-hours: Nov 20, 2024, 4:30 PM EST
Puma Biotechnology Revenue
Puma Biotechnology had revenue of $80.54M in the quarter ending September 30, 2024, with 43.53% growth. This brings the company's revenue in the last twelve months to $243.57M, up 6.30% year-over-year. In the year 2023, Puma Biotechnology had annual revenue of $235.64M with 3.34% growth.
Revenue (ttm)
$243.57M
Revenue Growth
+6.30%
P/S Ratio
0.56
Revenue / Employee
$1,316,589
Employees
185
Market Cap
139.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 235.64M | 7.61M | 3.34% |
Dec 31, 2022 | 228.03M | -25.12M | -9.92% |
Dec 31, 2021 | 253.16M | 28.05M | 12.46% |
Dec 31, 2020 | 225.11M | -47.15M | -17.32% |
Dec 31, 2019 | 272.26M | 21.27M | 8.47% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pro-Dex | 56.80M |
Sensus Healthcare | 41.31M |
Seer, Inc. | 14.61M |
Cardiff Oncology | 688.00K |
Zentek | 29.13K |
Inhibikase Therapeutics | 1.00 |
PBYI News
- 1 day ago - Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer - Business Wire
- 13 days ago - Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - Puma Biotechnology Reports Third Quarter 2024 Financial Results - Business Wire
- 15 days ago - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - Business Wire
- 2 months ago - Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 3 months ago - Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Puma Biotechnology Reports Second Quarter Financial Results - Business Wire